Silexion Therapeutics announces 1-for-9 reverse share split to maintain Nasdaq compliance

From GlobeNewswire: 2024-11-22 16:30:00

Silexion Therapeutics Corp. announced a 1-for-9 reverse share split effective November 27, 2024, with trading on a split-adjusted basis starting November 29, 2024. Shareholders will automatically receive one share for every nine shares held, with no fractional shares issued. The reverse split aims to maintain Nasdaq compliance and support future growth. Shareholders in book-entry form or through a broker do not need to take action. The split, designed to address short-term share price volatility, aligns with Nasdaq standards and strategic growth initiatives. Silexion focuses on developing RNAi therapies for KRAS-driven cancers, with promising results in pancreatic cancer trials and advancements in preclinical studies.



Read more at GlobeNewswire: Silexion Therapeutics Announces 1-for-9 Reverse Share